5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression

Prostate

Volumn 71, Issue 10, 2011, Pages 1033-1046

  Godoy, Alejandro ^a   Kawinski, Elzbieta ^a   Li, Yun ^a   Oka, Daizo ^a   Alexiev, Borislav ^a   Azzouni, Faris ^a   Titus, Mark A ^a   Mohler, James L ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 reductases; androgen metabolism; benign prostatic hyperplasia; castration recurrent prostate cancer; dihydrotestosterone

Indexed keywords

ANDROGEN; MONOCLONAL ANTIBODY; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM BASAL CELL; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SKELETAL MUSCLE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MUSCLE, SKELETAL; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 79955796493     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21318     Document Type: Article

References (56)

1. Labrie F,. Intracrinology. Mol Cell Endocrinol 1991; 78 (3): C113-118.
2. Russell DW, Wilson JD,. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61.
3. Hawk E, Breslow RA, Graubard BI,. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2000; 9 (5): 523-527. (Pubitemid 30313897)
4. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS,. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55 (6): 1014-1023. (Pubitemid 44716474)
5. Napalkov P, Maisonneuve P, Boyle P,. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995; 46 (3 Suppl A): 41-46.
6. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET,. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63 (4): 709-715. (Pubitemid 38479415)
7. Jemal A, Siegel R, Xu J, Ward E,. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224. (Pubitemid 36859473)
9. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
10. Walsh PC,. Chemoprevention of prostate cancer. N Engl J Med 2010; 362 (13): 1237-1238.
11. Denmeade SR, Lin XS, Isaacs JT,. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28 (4): 251-265. (Pubitemid 26119117)
12. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H,. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998; 35 (1): 63-70. (Pubitemid 28158639)
13. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH,. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997; 31 (1): 1-6. (Pubitemid 27058095)
14. Mohler JL, Gregory CW, Ford OH, III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448. (Pubitemid 38173980)
15. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP,. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001; 20 (46): 6718-6723. (Pubitemid 33020600)
16. Arnold JT, Isaacs JT,. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 2002; 9 (1): 61-73. (Pubitemid 34298364)
17. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45. (Pubitemid 33741879)
18. Gelmann EP,. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20 (13): 3001-3015. (Pubitemid 34728896)
19. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, III, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL,. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66 (21): 10594-10602. (Pubitemid 44799783)
20. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61 (11): 4315-4319. (Pubitemid 32685750)
21. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y,. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10 (4): 309-319. (Pubitemid 44512189)
22. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE,. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104 (20): 8438-8443. (Pubitemid 47175506)
23. Ponguta LA, Gregory CW, French FS, Wilson EM,. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008; 283 (30): 20989-21001.
24. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G,. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989; 32 (5): 695-698. (Pubitemid 19176012)
25. Geller J, Albert J, Loza D,. Steroid levels in cancer of the prostate-markers of tumour differentiation and adequacy of anti-androgen therapy. J Steroid Biochem 1979; 11 (1B): 631-636. (Pubitemid 9245942)
26. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL,. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11 (13): 4653-4657. (Pubitemid 41557182)
27. Fleshner NE, Trachtenberg J,. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. J Urol 1995; 154 (5): 1642-1645; discussion 1645-1646.
28. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM,. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279 (8): 7119-7130. (Pubitemid 38248859)
29. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
30. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68 (15): 6407-6415.
31. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S,. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 2004; 36 (1): 40-45. (Pubitemid 38056206)
32. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H,. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99 (1): 81-86. (Pubitemid 350239034)
33. Kohler G, Milstein C,. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495-497.
34. Coller HA, Coller BS,. Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. Hybridoma 1983; 2 (1): 91-96. (Pubitemid 13085611)
35. Godoy A, Ormazabal V, Moraga-Cid G, Zuniga FA, Sotomayor P, Barra V, Vasquez O, Montecinos V, Mardones L, Guzman C, Villagran M, Aguayo LG, Onate SA, Reyes AM, Carcamo JG, Rivas CI, Vera JC,. Mechanistic insights and functional determinants of the transport cycle of the ascorbic acid transporter SVCT2. Activation by sodium and absolute dependence on bivalent cations. J Biol Chem 2007; 282 (1): 615-624. (Pubitemid 47076637)
36. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ,. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008; 149 (6): 2959-2969. (Pubitemid 351724500)
37. Thigpen AE, Cala KM, Russell DW,. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. J Biol Chem 1993; 268 (23): 17404-17412. (Pubitemid 23236981)
38. Ford OH, III, Gregory CW, Kim D, Smitherman AB, Mohler JL,. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170 (5): 1817-1821. (Pubitemid 37254935)
39. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM,. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7 (4): 523-535.
40. Mahajan NP, Whang YE, Mohler JL, Earp HS,. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 2005; 65 (22): 10514-10523. (Pubitemid 41743747)
41. Majumder S, Liu Y, Ford OH, III, Mohler JL, Whang YE,. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 2006; 66 (12): 1292-1301. (Pubitemid 44384306)
42. Singh SS, Qaqish B, Johnson JL, Ford OH, III, Foley JF, Maygarden SJ, Mohler JL,. Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. Anal Quant Cytol Histol 2004; 26 (4): 194-200. (Pubitemid 39100905)
43. Smitherman AB, Mohler JL, Maygarden SJ, Ornstein DK,. Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J Urol 2004; 171 (2 Pt 1): 916-920. (Pubitemid 38090533)
44. Titus MA, Gregory CW, Ford OH, III, Schell MJ, Maygarden SJ, Mohler JL,. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11 (12): 4365-4371. (Pubitemid 40825625)
45. Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H, Wilson EM, Mohler JL, French FS,. 14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer. Clin Cancer Res 2009; 15 (24): 7571-7581.
46. Sotomayor P, Godoy A, Smith GJ, Huss WJ,. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69 (4): 401-410.
47. Miyamoto KK, McSherry SA, Dent GA, Sar M, Wilson EM, French FS, Sharief Y, Mohler JL,. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993; 149 (5): 1015-1019. (Pubitemid 23133761)
48. Singh SS, Kim D, Mohler JL,. Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. Biomed Eng Online 2005; 4 (1): 31.
49. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL,. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 2009; 181 (2): 621-626.
50. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R,. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10 (2): 149-154. (Pubitemid 46881666)
51. Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D,. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action. Urology 2004; 63 (1): 114-119. (Pubitemid 38147562)
52. Yamana K, Labrie F, Luu-The V,. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than type 1 and type 3 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Invest 2010; 2 (3): 293-299.
53. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blumel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG,. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010; 142 (2): 203-217.
54. McNeal JE, Bostwick DG,. Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 1986; 17 (1): 64-71. (Pubitemid 16163546)
55. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS,. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63 (3): 231-239. (Pubitemid 40571057)
56. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.